Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T cell therapy for patients with advanced renal cell carcinoma
2016-001454-18Phase 2Completed
- Sponsor
- Center for Cancer Immune Therapy
- Start
- Jul 2016
- Modality
- Cell Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of GC101 TIL + pembrolizumab in renal cell carcinoma (RCC), sponsored by Center for Cancer Immune Therapy. Primary endpoints: Toxicity and Feasibility. Started Jul 2016; status: completed.
02
Drugs
GC101 TIL + pembrolizumab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2016-001454-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001454-18.